Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CAM comment deadline

This article was originally published in The Tan Sheet

Executive Summary

The comment period for FDA's draft guidance entitled "Complementary and Alternative Medicine Products and Their Regulation by the Food and Drug Administration" is currently still scheduled to end on April 30, a spokesperson for the agency said April 19. The American Herbal Products Association told FDA in an April 16 1letter the April 30 deadline in the Federal Register 2notice was incongruous with the 90-day comment period specified in the 3guidance. "It is AHPA's intent to file its comments on the draft guidance on or before May 29, 2007, the date set out in the draft guidance," AHPA General Counsel Tony Young (Kleinfeld, Kaplan & Becker) writes in the letter. "AHPA urges FDA to clarify this date error at the earliest opportunity, so that the general public will be timely informed of the correct date for filing of comments in this matter," he adds...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS100417

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel